JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benke, D.
Right arrow Articles by Mohler, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benke, D.
Right arrow Articles by Mohler, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 38, 27323-27330, September 17, 1999


gamma -Aminobutyric Acid Type B Receptor Splice Variant Proteins GBR1a and GBR1b Are Both Associated with GBR2 in Situ and Display Differential Regional and Subcellular Distribution*

Dietmar BenkeDagger , Michael Honer, Claudia Michel, Bernhard Bettler§, and Hanns Mohler

From the Institute of Pharmacology, Swiss Federal Institute and Technology (ETH) and University of Zurich, CH-8057 Zurich and § Nervous System Research, Novartis Pharma AG, CH-4002 Basel, Switzerland

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The subunit architecture of gamma -aminobutyric acid, type B (GABAB), receptors in situ is largely unknown. The GABAB receptor variants, characterized by the constituents GBR1a and GBR1b, were therefore analyzed with regard to their subunit composition as well as their regional and subcellular distribution in situ. The analysis was based on the use of antisera recognizing selectively GBR1a, GBR1b, and GBR2. Following their solubilization, GBR1a and GBR1b were both found by immunoprecipitation to occur as heterodimers associated with GBR2. Furthermore, monomers of GBR1a, GBR1b, or GBR2 were not detectable, suggesting that practically all GABAB receptors are heterodimers in situ. Finally, there was no evidence for an association of GBR1a with GBR1b indicating that these two constituents represent two different receptor populations. A size determination of solubilized GABAB receptors by sucrose density centrifugation revealed two distinct peaks of which one corresponded to dimeric receptors, and the higher molecular weight peak pointed to the presence of yet unknown receptor-associated proteins. The distribution and relative abundance of GBR2 immunoreactivity corresponded in all brain regions to that of the sum of GBR1a and GBR1b, supporting the view that most if not all GBR1 proteins are associated with GBR2. However, GBR1a was present preferentially at postsynaptic densities, whereas GBR1b may be mainly attributed to presynaptic or extrasynaptic sites. Thus, GBR1a and GBR1b are both associated with GBR2 to form heterodimers at mainly different subcellular locations where they are expected to subserve different functions.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inhibitory neurotransmission is mainly mediated by gamma -aminobutyric acid (GABA)1 that displays a fast and a slow component. Whereas the fast inhibitory response results from the activation of the postsynaptically localized GABAA receptors by triggering the opening of an integral Cl- channel, the slow GABA action is mediated by the metabotropic GABAB receptors. GABAB receptors can be localized pre- and postsynaptically, where they interact via G-proteins with a variety of effector systems (reviewed in Refs. 1 and 2). Postsynaptic GABAB receptors activate K+ channels and regulate adenylyl cyclase. Presynaptic GABAB receptors inhibit the release of neurotransmitters by modulation of Ca2+ channels.

Despite the various functions of GABAB receptors, molecular cloning initially revealed only two receptor subtypes generated by alternative splicing of a single gene. These variants of the GABAB receptor, termed GBR1a and GBR1b, differ solely in their N terminus, where the first 147 residues of GBR1a are replaced by a sequence of 18 different amino acids in GBR1b (3). In situ hybridization histochemistry (3) and immunohistochemistry (4) with probes that did not discriminate between the GBR1a and GBR1b variants suggested that GBR1a and GBR1b represent the vast majority of GABAB receptors since their widespread distribution resembled that of GABAB receptors detected by autoradiography using radioligands. However, GBR1a and GBR1b expressed in COS-1 cells displayed up to 150-fold lower affinity for agonists compared with native GABAB receptors, and coupling of GBR1 to certain effector systems was difficult to demonstrate (3, 5). An explanation for this discrepancy was provided by the observation that GBR1 remained largely trapped in the endoplasmic reticulum when expressed transiently in mammalian cells (6). Recently, a second seven-transmembrane domain component of GABAB receptors, GBR2, was identified, which is similar in size to GBR1 and shares about 35% sequence identity (7-11). Upon co-expression in heterologous expression systems GBR1 and GBR2 formed heteromers, which were targeted to the cell surface membrane and displayed robust activation of G-protein-regulated K+ channels as well as inhibition of forskolin-induced cAMP production with half-maximal effector concentrations similar to those observed for native GABAB receptors (7-11). Thus, unlike other G-protein-coupled receptors, functional GABAB receptors appear to be heteromers formed from two related seven-transmembrane domain proteins, GBR1 and GBR2. However, there is evidence that also GBR1a and GBR1b alone were able to couple to K+ channels or adenylyl cyclase, although at low efficiency (3, 12). In addition, GBR2 expressed in HEK 293 cells was found to inhibit forskolin-stimulated cAMP production in the presence of GABA (8). Thus, GABAB receptors with monomeric or diverse, yet unknown, heteromeric structures may occur in vivo. It was therefore tested whether both GBR1a and GBR1b are associated with GBR2 in situ and whether GBR1a and GBR1b may be co-assembled to provide further receptor heterogeneity. In addition, it was analyzed whether the GABAB receptor components GBR1a, GBR1b, or GBR2 may also be present as monomers in situ and thereby contribute to further receptor heterogeneity. Finally, the regional and subcellular distributions of GBR1a, GBR1b, and GBR2 were analyzed to detect possible differential localizations, which may point to distinct functions of GABAB receptor subtypes. For this purpose variant-selective antisera were used to immunobiochemically characterize the GBR1a and GBR1b subtypes and their relationship to GBR2. The results indicate that GBR1a and GBR1b represent distinct GABAB receptor subtypes, which are targeted to largely different subcellular locations. Both GBR1a and GBR1b exist as heterodimers in combination with GBR2. There was no evidence for the presence of a major population of monomeric receptors. Most remarkably, after solubilization, the two GABAB receptor variants were both found to exist in two forms differing in molecular size. Thus, receptor-associated components may contribute further to the heterogeneity of GABAB receptors.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Generation of Antibodies-- For production of variant-specific antisera the following peptides were custom-synthesized (ANAWA Trading SA, Switzerland): N-terminal amino acids 83-107 of the GBR1a variant (sequence, CSKSYLTLENGKVFLTGGDLPALDG), N-terminal amino acids 1-18 of the GBR1b variant (sequence, SHSPHLPRPHPRVPPHPS containing an additional cysteine at the C terminus), and the C-terminal amino acids 922-944 common to both GABAB receptor variants (sequence, PRGPSEPPDRLSSDGSRVHLLYK, containing an additional cysteine at the N terminus; a naturally occurring cysteine at position 13 was exchanged by a serine to allow defined coupling to the carrier protein). The peptides were coupled via the cysteine residue to keyhole limpet hemocyanin and used for immunizing rabbits as described previously (13). All resulting antisera were purified by affinity chromatography using the peptide antigens coupled to thiopropyl-Sepharose 6B as matrix (13).

For detection of GBR2, affinity purified antiserum AbC22 (GBR2 antiserum) was used, which was raised against a glutathione S-transferase fusion protein corresponding to the amino acids 806-907 of GBR2 (for details see Ref. 7).

Preparation of Crude Brain Membranes and Subcellular Fractionation-- Brain tissue from male Harlan Sprague-Dawley rats (200-250 g) was homogenized in 10 volumes of 5 mM Tris/HCl, pH 7.4, containing 0.32 M sucrose and centrifuged for 15 min at 1000 × g. The crude membrane fraction was obtained by centrifugation of the resulting supernatant for 30 min at 17,000 × g. The membranes were washed twice with 50 mM Tris/HCl, pH 7.4, resuspended in the same buffer to give a protein concentration of about 5 mg/ml, and stored at -30 °C.

Subcellular fractionation and isolation of postsynaptic densities (PSD) were done according to Ref. 14. Cortex and hippocampus of adult rats were rapidly dissected and homogenized (10% w/v) in 0.32 M sucrose, 1 mM NaHCO3, 1 mM MgCl2, 0.5 mM CaCl2 (buffer A) by 12 up and down strokes with a motor-operated Teflon-glass homogenization. The homogenate was centrifuged for 10 min at 1500 × g, and the resulting pellet (P1) was washed once with buffer A by homogenization and centrifugation for 10 min at 755 × g. The combined supernatants were centrifuged for 10 min at 17,300 × g resulting in the crude membrane preparation (P2). The pellet was washed once in buffer A, resuspended in 0.32 M sucrose, 1 mM NaHCO3 (buffer B) and centrifuged for 120 min at 100,000 × g on discontinuous sucrose gradients (each 9 ml contained 1.2, 1, and 0.85 M sucrose containing 1 mM NaHCO3). The band between 1.0 and 1.2 M sucrose was removed, diluted with buffer B, and centrifuged for 20 min at 48,200 × g. The resulting synaptosomal membranes (SPM) were resuspended in 25 mM Tris, pH 7.3, containing 0.5% Triton X-100 to a protein concentration of 4 mg/ml, stirred on ice for 15 min, followed by centrifugation for 20 min at 48,200 × g. The pellet was resuspended in 50 mM Tris, pH 7.3, and postsynaptic densities (PSD) were isolated by centrifugation for 120 min at 275,000 × g on a discontinuous sucrose gradient (each 3 ml contained 2, 1.5, and 1 M sucrose containing 1 mM NaHCO3). The PSD fraction (band between 1.5 and 2 M sucrose) was diluted to 5.5 ml with H2O followed by addition of an equal volume of 1% Triton X-100, 150 mM KCl, incubated for 60 min on ice and pelleted by centrifugation for 60 min at 275,000 × g.

Further subcellular fractions were prepared as follows. The supernatant of the crude membrane preparation (S2) was centrifuged for 60 min at 100,000 × g to obtain microsomal membranes (P3) and the cytosolic fraction (S3). The synaptosomal fraction (SPM) was resuspended in 5 mM Tris, pH 7.3, 1 mM EDTA, 0.05% Triton X-100 and subjected to osmotic lysis for 60 min on ice followed by centrifugation for 20 min at 48,200 × g resulting in the lysed synaptosomal membranes (LP1) and the cytosolic synaptosomal fraction (LS1).

Western Blotting-- Aliquots of the crude membranes or subcellular fractions were incubated for 15 min at 60 °C with an equal volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol, 0.002% bromphenol blue, 10% beta -mercaptoethanol, 4% SDS and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 7.5% mini-gels (Mini Protean II, Bio-Rad). Proteins were transferred onto polyvinylidene difluoride or nitrocellulose membranes in a semi-dry electro-blotting apparatus (Trans-Blot, Bio-Rad) at 15 V for 60 min using 39 mM glycine, 48 mM Tris, 0.04% SDS as transfer buffer. For immunodetection, the blots were blocked for 1-2 h in TBST (10 mM Tris/HCl, pH 8, 0.15 M NaCl, 0.05% Tween 20) containing 5% non-fat dry milk (=blocker) at room temperature, followed by incubation with affinity purified antisera overnight at 4 °C in TBST, 5% blocker. The blots were washed one time for 10 min with 20 mM Tris, pH 7.5, 60 mM NaCl, 2 mM EDTA, 0.4% SDS, 0.4% Triton X-100, 0.4% deoxycholate and three times with TBST. Incubation with secondary antibodies (horseradish peroxidase-conjugated goat anti-rabbit IgG diluted 1:5000 in TBST, 5% blocker; Promega) was carried out for 1 h at room temperature. Following extensive washing (see above), immunoreactivity was detected by the chemiluminescence method (Western Blot Chemiluminescence Reagent Plus; NEN Life Science Products).

Quantification of immunoreactive bands was performed with a high resolution computer-based image analysis system (MCID M2, Imaging Research, Ontario, Canada). To ensure an analysis in the linear ranges, x-ray films were exposed to Western blots of increasing protein concentrations (2.5-40 µg) for various times.

Solubilization of GABAB Receptors-- For solubilization of GABAB receptors, crude membranes were thawed and washed once with 10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 200 mg/l bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 2.3 mg/liter aprotinin, 1 mM benzamidine, 0.05% phosphatidylcholine and resuspended in the same buffer to give a protein concentration of 5 mg/ml. Following addition of the detergent (either 1% Triton X-100, 0.5% sodium deoxycholate, 2% CHAPS, 2% BigCHAP, 2% octyl-beta -D-glucopyranoside or RIPA (0.5% sodium deoxycholate), 1% Nonidet P-40, 0.1% SDS; final concentrations), the mixture was incubated for 30 min on ice, and insoluble material was removed by centrifugation for 60 min at 100,000 × g. The supernatant was carefully removed, and the remaining pellet was resuspended in buffer to the original volume. To test the solubilization efficiency, equal aliquots of the supernatant and pellet were subjected to Western blotting.

Sucrose Density Gradient Centrifugation-- Linear gradients were prepared from 5 and 20% sucrose in 50 mM Tris/HCl, pH 8.0, 0.02% NaN3 containing either 0.1% deoxycholate or 0.5% Triton X-100. Deoxycholate extracts of brain membranes (200 µl, see above) were layered on the top of each gradient and were centrifuged at 170,000 × g for 14 h at 4 °C. At the end of the centrifugation, fractions of 300 µl were collected and analyzed for GBR1 and GBR2 immunoreactivity (IR) by Western blotting. For calibration, marker proteins (2 mg/ml bovine serum albumin, aldolase, and catalase, were dissolved in 10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 200 mg/liter bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 2.3 mg/liter aprotinin, 1 mM benzamidine, 0.05% phosphatidylcholine, 0.5% deoxycholate and applied to gradients run in parallel. The presence of marker proteins in each fraction was determined by SDS-PAGE and by measuring the optical density of the fractions at a wavelength of 280 nm. In addition, the position of GABAA receptors was determined by Western blotting using antisera against the alpha 1- and alpha 3-subunits (15).

Immunoaffinity Chromatography-- For construction of a GBR1b-specific immunoaffinity column, affinity purified antibodies were coupled to protein A-agarose as described previously (16). Crude membranes prepared from whole rat brain were solubilized in 0.5% deoxycholate as described above and circulated through the columns overnight at 4 °C. The columns were extensively washed with 50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 0.1% deoxycholate, 0.02% NaN3 followed by 5 mM Tris/HCl, pH 8.0, 0.1% deoxycholate. Bound receptors were eluted with 0.1 M Na2HPO4, pH 11.5, 0.5 M urea, 0.1% deoxycholate, immediately neutralized with 1 M NaH2PO4, concentrated by ultrafiltration (Centricon 30 concentrators, Amicon Inc.), and subjected to Western blot analysis.

Histoblotting-- The regional distribution of the GBR1a, GBR1b, and GBR2 proteins in the adult rat brain was analyzed using the histoblot technique as described previously (17-19). Parasagittal cryostat-cut sections (16 µm) of rat brains were collected onto nitrocellulose membranes (0.45 µm, Bio-Rad) and kept frozen at -30 °C until use. For protein transfer, the frozen nitrocellulose sheets containing the brain sections were moistened with 39 mM glycine, 48 mM Tris, 20% methanol, 2% SDS and incubated for 5 min at room temperature. After 2 h of incubation in TBST, 5% blocker, the blots were washed with TBST and incubated overnight with gentle agitation in 0.1 M Tris, pH 6.8, 2% SDS, 0.1 M beta -mercaptoethanol at room temperature to remove the brain tissue and denature the proteins bound to the nitrocellulose membranes. Following washing with TBST, histoblots were processed for immunostaining with the GBR1a-, GBR1b-, GBR1a/b-, and GBR2-selective antisera as described for Western blotting.

Cell Culture and Transfection-- Human embryonic kidney cells (ATCC CRL 1573, 293 cells) were grown on culture dishes (9 cm) in minimal essential medium (Life Technologies, Inc.) supplemented with 8% heat-inactivated fetal calf serum and 10 µg/ml gentamycin. Cells were transfected with 30 µg of GBR1a or GBR1b variant expression plasmids using the calcium phosphate precipitation technique. For harvesting, culture dishes were washed with ice-cold buffer (10 mM Tris/HCl, pH 7.4, 0.32 M sucrose, 5 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride) followed by scraping the cells in buffer and centrifugation at 3,000 × g for 10 min. The cell pellets were stored at -80 °C until used. For Western blotting, the cells were thawed, resuspended in 50 mM Tris/HCl, pH 7.4, 150 mM KCl, homogenized, and washed twice with buffer.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Generation and Characterization of Splice Variant-selective Antisera-- Affinity purified polyclonal antisera directed against the GABAB receptor splice variants GBR1a and GBR1b were generated using synthetic peptides derived from the N-terminal domain, which differs between the two splice variants (GBR1a-(83-107) and GBR1b-(1-18)). In addition, an antiserum was raised against the C terminus common to both splice variants (GBR1a,b-(922-944)). On Western blots of crude rat brain membranes, the GBR1a-(83-107) antiserum detected a broad protein band of 130 kDa, the GBR1b-(1-18) antiserum a broad protein band of 100 kDa, and the GBR1a,b-(922-944) antiserum correspondingly two proteins of 100 and 130 kDa, respectively (Fig. 1A). The immunoreactivities (IR) were completely prevented by co-incubation of the antisera with the corresponding peptide antigens underscoring the specificity of the antisera (Fig. 1A). Since the GBR1a-(83-107) and GBR1b-(1-18) antisera recognized proteins of distinct sizes, a cross-reactivity of the antisera was not expected. To assess further the variant selectivity of the antisera, human embryonic kidney (HEK 293) cells were transfected with the GBR1a or GBR1b clone and analyzed by Western blotting for the presence of the respective variants. In HEK 293 cells expressing the GBR1a variant, a 130-kDa protein was stained by the GBR1a-(83-107) and GBR1a,b-(922-944) antisera, whereas no IR was found with the GBR1b-(1-18) antiserum (Fig. 1B). Conversely, in HEK 293 cells expressing the GBR1b variant, a 100-kDa protein was detected with the GBR1b-(1-18) and GBR1a,b-(922-944) antisera, but no IR was observed with the GBR1a-(83-107) antiserum (Fig. 1B). In controls with non-transfected cells none of the antisera showed an IR. Thus, the GBR1a-(83-107) and GBR1b-(1-18) antisera were specific for the GABAB receptors' splice variants GBR1a and GBR1b and lacked any cross-reactivity. The selectivity of the GBR2 antiserum was described previously (7).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Immunochemical identification of the GBR1a and GBR1b variants. A, proteins from crude rat brain membranes (40 µg/lane) were subjected to SDS-PAGE and Western blotting with affinity purified GBR1a-(83-107) (0.7 µg/ml), GBR1a, b-(922-944) (0.2 µg/ml), or GBR1b-(1-18) antiserum (0.1 µg/ml) in the absence or presence of 10 µg/ml of the respective peptide antigen (+P). B, Western blot analysis of HEK 293 cells expressing the GBR1a or GBR1b variant. Membranes from HEK 293 cells expressing either the GBR1a or GBR1b variant were subjected to SDS-PAGE and Western blotting using the GBR1a-(83-107), GBR1b-(1-18) or GBR1a,b-(922-944) antiserum.

Native GABAB Receptor Subtypes Are Heterodimers-- Recent studies on mainly recombinant receptors indicated that fully functional GABAB receptors are heterodimers assembled from GBR1 and GBR2 (7-10). To test whether an association of GBR1 with GBR2 also holds for the native GABAB receptor variants, immunopurification experiments were performed. As a prerequisite, optimal solubilization conditions were determined. Crude brain membranes were treated with different detergents followed by Western blot analysis of both the extract and insoluble material using the GBR1a,b-(922-944) antiserum. Among the detergents tested, the ionic detergent deoxycholate (0.5%) and the detergent mixture RIPA (0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS) solubilized both GABAB receptor variants most efficiently (Fig. 2). All non-ionic and zwitterionic detergents tested (1% Triton X-100, 2% CHAPS, 2% BigCHAP, and 2% octyl-beta -D-glucopyranoside) were considerably less effective in solubilization (Fig. 2). There was no apparent difference in the efficiency of extracting GBR1a compared with GBR1b. Thus, deoxycholate was the detergent of choice for solubilization of both GABAB receptor variants. Increasing the deoxycholate concentration to 1.5% and the ionic strength to 1 M NaCl did not improve the solubilization efficiency (not shown). Quantification of the amount of solubilized GABAB receptor protein by densitometric analysis of Western blots revealed that 58 ± 5% (n = 6) of the GBR1a variant and 56 ± 5% (n = 6) of the GBR1b variant were solubilized by 0.5% deoxycholate.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Solubilization of GABAB receptors. Crude rat brain membranes (5 mg/ml) were incubated for 30 min on ice with either 1% Triton X-100, 0.5% deoxycholate, RIPA (0.5% sodium deoxycholate (DOC), 1% Nonidet P-40, 0.1% SDS), 2% CHAPS, 2% Big-CHAP, or 2% octyl-beta -D-glucopyranoside (OGP) followed by centrifugation at 100,000 × g. The supernatant was carefully removed, and the remaining pellet was resuspended in buffer to the original volume. Equal aliquots of the supernatant (S) and pellet (P) were subjected to Western blotting using the GBR1a,b-(922-944) antiserum to test for the solubilization efficiency. Control refers to membranes treated with buffer instead of detergent.

The ability of GBR1a and GBR1b to associate with GBR2 was analyzed by immunoprecipitating GABAB receptors from deoxycholate extracts of brain membranes using the GBR2 antiserum. In the well washed immunoprecipitate an IR for both GBR1a and GBR1b was detected on Western blots with the GBR1a,b-(922-944) antiserum, demonstrating that both GBR1a and GBR1b are associated with GBR2 in native GABAB receptors (Fig. 3A). In addition, the possible presence of trimeric receptors made up of GBR1a, GBR1b, and GBR2 was investigated. For this purpose, immunoaffinity chromatography of deoxycholate extracts of brain membranes was performed using GBR1b antibodies coupled to protein A-agarose. GBR1b antibodies were chosen for construction of the immunoaffinity column since GBR1a antibodies lost their activity upon coupling to protein A-agarose. Following extensive washing of the column, bound proteins were eluted with 0.1 M Na2HPO4, pH 11.5, and analyzed by Western blotting. On Western blots of receptors immunoisolated with GBR1b antibodies, only signals for GBR1b and GBR2 were observed but not for GBR1a (Fig. 3B). Consequently, GBR1a and GBR1b do not appear to co-assemble to a measurable extent in situ. Thus, native GBR1a and GBR1b represent distinct receptor subtypes, which are both associated with GBR2 to form heteromers in situ.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Constituents of GABAB receptors identified by immunoprecipitation and immunoaffinity purification. A, GABAB receptors were immunoprecipitated from deoxycholate extracts of whole rat brain membranes with the GBR2 antiserum followed by Western blot analysis using GBR1a,b-(922-944) and GBR2 antiserum. IR of GBR1a, GBR1b, and GBR2 is indicated by 1a, 1b, and 2, respectively. B, deoxycholate extracts of whole rat brain membranes were applied to a column containing the GBR1b-(1-18) antibodies coupled to protein A-Sepharose. After washing, the eluates were analyzed for the presence of GBR1a, GBR1b, and GBR2 proteins by Western blotting using the GBR1a-(83-107), GBR1a,b-(922-944), GBR1b-(1-18), and GBR2 antiserum. +P indicates co-incubation of the antiserum with 10 µg/ml of the respective peptide antigen. A weak nonspecifically labeled protein band at about 170 kDa was occasionally observed.

Native GABAB Receptor Variants Each Occur in Two Molecular Forms-- To assess whether the constituent proteins of GABAB receptors, in addition to forming heteromers, may also occur as monomers or homo-oligomers, the molecular size of native solubilized receptors was analyzed by sucrose density gradient centrifugation. Proteins of rat brain membranes were extracted with 0.5% deoxycholate and subjected to 5-20% linear sucrose density gradient centrifugation, followed by an analysis of the pattern of distribution of GBR1a and GBR1b and GBR2. Western blotting revealed IR for GBR1a, GBR1b, and GBR2 in the same fractions, pointing to their co-sedimentation. The relative staining intensity of GBR2 roughly corresponded to that of GB1a and GB1b IR, in line with the association of GBR1 and GBR2 (Fig. 4). Surprisingly, the two GBR1 proteins and the GBR2 protein were present in two distinct peaks. The first broad peak, containing the majority of GBR1a, GBR1b, and GBR2 proteins, migrated to a position between that of the marker proteins aldolase (158 kDa) and catalase (232 kDa) and overlapped with GABAA receptors as marker protein (~250 kDa). The second receptor fraction migrated slightly further into the gradient than the GABAA receptor marker, suggesting a molecular size of >250 kDa. The two molecular forms of GABAB receptors were found irrespective of the detergent used. Solubilization of GABAB receptors with Triton X-100 (1%) or CHAPS (2%) and inclusion of the respective detergent in the sucrose density gradients resulted likewise in the high and low molecular forms (not shown). Both molecular forms of GABAB receptors were also detected by size-exclusion chromatography on a Superose 6HR 10/30 column using a fast liquid chromatography system (Amersham Pharmacia Biotech) (not shown). Most importantly, since GABAB receptor IR was not eluted in the void volume of the column, it is unlikely that GABAB receptors strongly aggregate nonspecifically under the conditions used. The high molecular form of GABAB receptors is therefore not expected to represent aggregated receptor protein.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   Sucrose density gradient centrifugation of native GABAB receptors. Deoxycholate extracts of rat brain membranes (200 µl) were layered on 5-20% linear sucrose density gradients and centrifuged at 170,000 × g for 14 h at 4 °C. A, after fractionation, individual fractions were analyzed for GBR1a and GBR1b IR by Western blotting using the GBR1a,b-(922-944) antiserum. For comparison, the migration of GABAA receptors (~250 kDa) was probed with a alpha 3-subunit-specific antiserum. The position of marker proteins (bovine serum albumin, aldolase, and catalase) is indicated on the top. B, the association of GBR1 with GBR2 proteins in the high and low molecular weight peak of GBR1 and GBR2 IR observed in the sucrose density gradients was analyzed in immunoprecipitation experiments. After fractionation, individual fractions were analyzed for GBR2 IR by Western blotting followed by immunoprecipitation of GABAB receptors from fractions displaying strong IR (fractions 6-7 and 13-16) using the GBR1a,b-(922-944) antiserum. The resulting immunoprecipitates were analyzed by Western blotting with the GBR1a,b-(922-944) and the GBR2 antiserum.

To demonstrate directly the association of GBR1 with GBR2 in both GABAB receptor peaks, GABAB receptors were immunoprecipitated from individual fractions taken from the high and low molecular weight forms (Fig. 4B). Immunoprecipitation was performed with the GBR1a,b-(922-944) antiserum, and the precipitate was tested for the presence of GBR1a, GBR1b, and GBR2 by Western blotting. In both, the high and low molecular size fractions GBR1a and GBR1b were co-precipitated with GBR2 (Fig. 4B).

Since in all fractions tested GBR1a and GBR1b were found to be associated with GBR2, it is unlikely that considerable amounts of monomeric GABAB receptors are present in brain. However, to rule out the existence of monomeric GABAB receptors, quantitative immunoprecipitation experiments were performed. GABAB receptor proteins GBR1a, GBR1b, or GBR2 were immunoprecipitated from deoxycholate extracts of brain membranes with the GBR1a,b-(922-944) or GBR2 antiserum, respectively. Following precipitation of the receptor-antibody complex with protein A-agarose the immunoprecipitation was repeated two times with the resulting supernatants to ensure quantitative depletion of either GBR1a and GBR1b or GBR2 by the respective antiserum. Western blot analysis revealed that neither in the GBR1a- and GBR1b-depleted supernatant nor in the GBR2-depleted extract either GBR2 or GBR1a/GBR1b were detectable (Fig. 5). This result indicated that no measurable population of monomeric or homo-oligomeric GBR1a, GBR1b, or GBR2 were present in the brain extracts.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 5.   Quantitative immunoprecipitation of GBR1a/GBR1b and GBR2 indicates the lack of monomeric and homo-oligomeric GABAB receptors in rat brain. Crude membranes prepared from whole rat brains (5 mg of protein/ml) were solubilized with 0.5% deoxycholate (final concentration) and centrifuged for 60 min at 100,000 × g, and aliquots of the resulting supernatant were subjected to immunoprecipitation with the GBR1a,b-(922-944) and the GBR2 antiserum. Antigen-antibody complexes were precipitated with protein A-agarose, and the immunoprecipitation was repeated two times with the resulting supernatants using the respective antiserum to ensure quantitative depletion of GBR1a/GBR1b or GBR2. Aliquots of the supernatant after the third cycle of immunoprecipitation and aliquots of the precipitates after the first (A), second (B), and third (C) cycle of immunoprecipitation were analyzed by Western blotting with the GBR1a,b-(922-944) and the GBR2 antiserum. C, controls run in parallel in which the antiserum was replaced by buffer; lane 1, immunoprecipitation with the GBR1a,b-(922-944) antiserum; lane 2, immunoprecipitation with the GBR2 antiserum.

Since GBR1a and GBR1b do not appear to heteromize (Fig. 3), the high molecular weight form of GABAB receptors (>250 kDa) identified in the sucrose density gradients is unlikely be due to the existence of multimeric complexes built up of GBR1a, GBR1b, and GBR2. It was therefore tested whether the differences in size of GABAB receptors is due to the formation of disulfide bridges, as demonstrated for metabotropic glutamate receptors (20). However, on Western blots performed under non-reducing conditions GBR1 and GBR2 proteins migrate as monomers, arguing against a dimerization via disulfide bridges. Likewise, inclusion of dithiothreitol (10 mM) into the sucrose density gradients did not affect the migration of GBR1a, GBR1b, or GBR2 (not shown). Thus, the high molecular weight forms may either be due to variations in the stoichiometry of the receptor subunits or due to the association of at least some GABAB receptors with yet unknown proteins.

Differential Regional Distribution of GBR1a and GBR1b-- On Western blots of whole brain membranes staining of the GBR1a variant was consistently weaker than that of the GBR1b variant when the GBR1a,b-(922-944) antiserum was used (Figs. 1 and 2). Since the GBR1a,b-(922-944) antiserum was raised against a peptide sequence that is identical in GBR1a and GBR1b proteins, the GBR1a,b-(922-944) antiserum permitted a direct comparison of the relative abundance of the GBR1a and GBR1b variants in brain tissue. Densitometric analysis of Western blots with increasing protein concentrations of membranes prepared from whole rat brains revealed that GBR1b is 2.1 ± 0.5 (n = 6)-fold more abundant than GBR1a (Fig. 6). Thus, the two GABAB receptor subtypes were expected to display a different distribution on the regional and cellular level in the brain. The regional distribution of GBR1a, GBR1b, and GBR2 proteins was analyzed by Western blotting using membranes prepared from seven major brain regions. All three GABAB receptor proteins displayed a widespread distribution, being present in all brain areas analyzed with the highest relative expression in the cerebral cortex and cerebellum (Fig. 7A). However, the presence of the GBR1 splice variants differed considerably among brain regions. Whereas GBR1a and GBR1b were expressed to a similar extent in the hippocampus, GBR1a predominated in the olfactory bulb and striatum, and GBR1b was more abundant than GBR1a in cerebral cortex, thalamus, cerebellum, and medulla. The staining intensity for GBR2, which appeared to correspond to the sum of GBR1a and GBR1b-IR in the different brain areas, was strongest in cerebral cortex, hippocampal formation, thalamus, and cerebellum, followed by the olfactory bulb, striatum, and medulla (Fig. 7A).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   Relative abundance of the GBR1a and GBR1b variants. Crude rat brain membranes containing increasing protein concentrations (2.5-40 µg) were subjected to Western blotting using the GBR1a,b-(922-944) antiserum (top). Quantification of immunoreactive bands was performed with a high resolution computer-based image analysis system (MCID M2, Imaging Research, Ontario, Canada). The densitometric analysis of the Western blots revealed that the GBR1b variant is 2.1 ± 0.5 (n = 6)-fold more abundant than the GBR1a variant.


View larger version (88K):
[in this window]
[in a new window]
 
Fig. 7.   Regional distribution of GBR1a, GBR1b, and GBR2 proteins in adult rat brain. A, equal amounts of crude membranes (40 µg of protein/lane) prepared from olfactory bulb (Olf. bulb), striatum, cerebral cortex, hippocampus, thalamus, cerebellum, and medulla/pons were analyzed for GBR1a-(83-107), GBR1a,b-(922-944), GBR1a,b-(922-944), and GBR2 immunoreactivity by Western blotting. B, GBR1a, GBR1b, GBR1a/b, and GBR2-IR were visualized in parasagittal rat brain sections (16 µm) blotted onto nitrocellulose membranes followed by immunostaining with the GBR1a-(83-107), GBR1a,b-(922-944), GBR1a,b-(922-944), or GBR2 antiserum. Co-incubation with the respective peptide antigens (10 µg/ml) completely prevented immunostaining, underlining its specificity (not shown).

The distribution of GBR1a, GBR1b, and GBR2 was analyzed in more detail in sections of adult rat brain. Since the GBR1a-(83-107) antiserum failed to recognize the GBR1a protein in perfusion-fixed brain tissue processed for immunohistochemistry, the histoblot technique was used (17-19). Parasagittal cryostat-cut sections were blotted onto nitrocellulose membranes, providing a protein image of the section for immunostaining performed according to the protocol of Western blotting (Fig. 7B). The histoblot technique offered very high sensitivity and high signal to noise ratios, making it the method of choice for an analysis of the gross regional distribution of GBR proteins, although lacking cellular resolution. GBR1a-IR was observed throughout the brain with higher than average levels in the external plexiform layer of the olfactory bulb, CA1 region of the hippocampus, superior colliculus, and striatum. GBR1b was distributed as widespread as GBR1a but displayed much larger regional differences in staining intensity. Strongest GBR1b-IR was seen in the thalamus, outer layers of the cerebral cortex, and molecular layer of the cerebellum, whereas moderate staining was observed in the hippocampus and amygdala, and faint staining was observed in the olfactory bulb, striatum, basal ganglia, mesencephalon, pons, and medulla. Interestingly, the sum of GBR1a and GBR1b patterns of distribution and staining intensities, as visualized with the GBR1a,b-(922-944) antiserum, strikingly matched that of GBR2 (Fig. 7B), supporting the view that GBR1a and GBR1b are both associated with GBR2 in all brain areas to form functional GABAB receptors.

Differential Subcellular Distribution of GBR1a and GBR1b Variants-- In order to analyze the subcellular distribution of GBR1a, GBR1b, and GBR2 proteins, homogenates of rat brain were fractionated by differential centrifugation. Western blot analysis of the various cellular subfractions demonstrated a distribution of GBR1a, GBR1b, and GBR2 proteins consistent with a synaptic membrane localization. All three proteins were enriched in fractions containing synaptic plasma membranes, i.e. synaptic plasma membranes (SPM) and lysed synaptic plasma membranes (LP-SPM) (Fig. 8). A potential postsynaptic localization of the GABAB receptor proteins GBR1a, GBR1b, and GBR2 was investigated by purifying PSD. PSDs are specializations of the cytoskeleton, located beneath the postsynaptic membrane, which forms a disc that consists of cytoskeletal and regulatory proteins, partially involved in the anchoring of neurotransmitter receptors (reviewed in Ref. 21). In highly purified PSDs (14) a striking difference in the enrichment of GBR1a and GBR1b variants was apparent. Whereas strong GBR1a-IR was detected in the PSD fraction, only faint signals were observed for the GBR1b variant (Fig. 8), suggesting that the GBR1a and GBR1b variants differ in their extent of postsynaptic localization. In addition, GBR1-IR and GBR2-IR was detected in fractions containing membranes of the endoplasmic reticulum and the Golgi apparatus (P3 and LS-SPM), pointing to the existence of an intracellular pool of GABAB receptors in neurons (Fig. 8).


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 8.   Subcellular distribution of GBR1a, GBR1b, and GBR2 proteins. Rat brain tissue was subjected to subcellular fractionation (for details see "Experimental Procedures"), and aliquots (30 µg) of each fraction were analyzed by Western blotting using the GBR1a-(83-107), GBR1b-(1-18), GBR1a,b-(922-944), and GBR2 antiserum. H, homogenate; P1, nuclear pellet; P2, crude membranes; SPM, synaptic plasma membranes; LP-SPM, lysed synaptosomal membranes; LS-SPM, cytosolic synaptosomal fractions (also contains synaptic vesicles and membranes of the endoplasmic reticulum and Golgi apparatus); P3, light membrane pellet (contains synaptic vesicles and membranes of the endoplasmic reticulum and Golgi apparatus); S3, cytosolic fraction (devoid of membranes); PSD, postsynaptic densities.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

For GABAB receptors, two constituent proteins with a seven-transmembrane domain topology, GBR1 and GBR2, are known, of which GBR1 exists in two splice variants (3, 7-11). In situ, the subunit composition of the two GABAB receptor variants is yet unknown. In the present study, the structural organization as well as the regional and subcellular distribution of the two GABAB receptor subtypes were analyzed in rat brain with antibodies selectively recognizing the GBR1a, GBR1b, or GBR2 proteins. The results suggest that GBR1a and GBR1b characterize two distinct receptor populations, which both contain GBR2. There was no indication for the presence of monomeric or homo-oligomeric GABAB receptor components. Most interestingly, determination of the size of native GABAB receptors pointed to the presence of yet unknown receptor associated proteins. Striking differences in the relative abundance of GBR1a and GBR1b as well as their regional and subcellular distribution suggest that they differ in their targeting specificity and may thus serve distinct functions in neuronal signaling.

Heteromerization of GBR1a and GBR1b with GBR2 in Rat Brain-- To date, the only examples for a heterodimerization of G-protein-coupled receptors are opioid receptors, which are able to form functional recombinant delta /kappa dimers (30), and GABAB receptors. Recombinant GABAB receptors are unique among seven-transmembrane domain receptors, as their targeting to the cell membrane and their efficient coupling to effector systems largely require the co-expression of the two constituent proteins GBR1 and GBR2 (7-11). In cerebral cortex both GBR1a and GBR1b were found to be associated with GBR2 as shown by immunoprecipitation of 125I-CGP 71872 photoaffinity labeled GABAB receptors (7). However, it was not clear whether GBR1a and GBR1b assemble with GBR2 in separate receptor subtypes or whether GABAB receptors consists of ternary complexes containing both GBR1a and GBR1b together with GBR2. Thus, variant-specific antisera were required for a detailed investigation of the molecular organization of native GABAB receptor subtypes.

Although their solubilization by deoxycholate was not quantitative (GBR1a, 58 ± 5%; GBR1b, 56 ± 5%), GBR1a and GBR1b were extracted to an equal extent (Fig. 2), ensuring comparable receptor concentrations in the supernatant. When solubilized GABAB receptors were immunopurified using GBR1b-(1-18) or GBR2 antibodies, both GBR1a and GBR1b were found to be associated with GBR2 (Figs. 3 and 4). Moreover, the results did not support the presence of GABAB receptors in which the two splice variants GBR1a and GBR1b were co-assembled (Fig. 3B). This result is further supported by the observation that the C termini of GBR1 and GBR2 do not form homo-oligomers in the yeast two-hybrid system (8, 10). Thus, the brain appears to largely contain two distinct receptor subtypes with the subunit combination GBR1a/GBR2 and GBR1b/GBR2. An association of GBR1a or GBR1b with GBR2 in native GABAB receptors is further substantiated by their overlapping pattern of distribution and relative abundance as detected by the histoblot technique on brain slices on a regional level (Fig. 7). The degree of GBR2 IR largely corresponded to the sum of GB1a and GBR1b IR.

Homomeric GABAB receptors have been suggested to be functional as tested in heterologous expression systems. This was based on the observation that GBR2 expressed in HEK 293 cells induced a decrease in forskolin-stimulated cAMP production to the same extent as that detected after co-expression of GBR1 with GBR2 (8). In addition, the coupling of GBR1 to adenylyl cyclase and K+ channels has been detected (3, 12). However, molecular size estimation of solubilized GABAB receptors using sucrose density gradient centrifugation did not reveal an indication for the presence of monomers for GBR1a, GBR1b, or GBR2 as detected by Western blotting. Moreover, quantitative immunoprecipitation of solubilized receptors with the GBR2 or the GBR1a,b-(922-944) antiserum resulted in the precipitation of the entire population of GABAB receptors; the supernatants did not contain any measurable amounts of excess GBR1a, GBR1b, or GBR2. Thus, there was no evidence for the presence of monomeric or homo-oligomeric forms of GABAB receptors in brain (Fig. 5).

Most interestingly, the molecular size estimation of native solubilized GABAB receptors by sucrose density gradient centrifugation revealed two different molecular forms. The lower molecular weight peak, which contained the majority of GABAB receptors, can be attributed to heterodimeric receptors GBR1a/GBR2 and GBR1b/GBR2. The receptor populations with the higher molecular size, which likewise contained GBR1a and GBR1b in association with GBR2, are unlikely to consist of heterotrimeric GBR1a/GBR1b/GBR2 receptors since GBR1b-specific immunoaffinity chromatography ruled out an association of GBR1b with GBR1a (Fig. 3). Furthermore, the high molecular weight GABAB receptors are not due to a dimerization via disulfide bridges, as in the case of metabotropic glutamate receptors, which, in contrast to GABAB receptors, contain four highly conserved cysteine residues in the N-terminal domain (20). Although metabotropic glutamate receptors migrate as dimers under non-reducing conditions (20), GBR1a, GBR1b, and GBR2 migrate as monomers. Thus, the high molecular forms of GBR1a/GBR2 and GBR1b/GBR2 may rather represent complexes with yet unidentified proteins, possibly involved in the regulation or anchoring of GABAB receptors. The coiled-coil domains in the C termini of GBR1 and GBR2 (8, 10) may be preferred sites of interaction with accessory proteins (22) in addition to the putative PDZ-interacting module at the GBR1 and the GBR2 C terminus (5).

Differential Regional Distribution and Subcellular Targeting of GBR1a and GBR1b-- In line with previous immunohistochemical evidence using the GBR1b-(1-18) and GBR1a,b-(922-944) antisera (4), the pattern and the sum of the staining intensities of GBR1a and GBR1b matched the distribution and staining intensity of GBR2 (Fig. 7). Furthermore, the regional pattern of the GABAB receptor proteins GBR1a, GBR1b, and GBR2 also corresponded to that of the respective mRNAs analyzed by in situ hybridization histochemistry (7-9). Finally, the distribution of GABAB receptor-binding sites detected autoradiographically (23-25) corresponded to the pattern of GABAB receptor proteins. Thus, the vast majority of GABAB receptors appear to consist of two isoforms with the subunit combinations GBR1a/GBR2 and GBR1b/GBR2. However, since GBR1a and GBR1b variants represent distinct GABAB receptor subtypes, they were expected to differ in their regional distribution. In general, the GB1b variant was more abundant than the GBR1a variant, although the latter predominated in some brain areas (e.g. olfactory bulb, striatum, and CAI region of the hippocampus; Fig. 7).

In some brain areas (olfactory bulb, striatum, and hypothalamus), the relative signal intensity of GBR2 mRNA in in situ hybridization histochemistry was considerably lower than that of GBR1 mRNA (7-9). This finding led to the suggestion that not all GBR1 proteins may be associated with GBR2. However, on the protein level, the ratio of GBR1 to GBR2 was not different from that in other brain areas (Fig. 7). The discrepancy between the mRNA and protein ratios suggests that GABAB receptors may be subject to regionally different transcriptional and/or post-transcriptional regulation. It will therefore be of interest to determine whether GABAB receptors are subject to regionally distinctive translational control.

Presynaptic GABAB receptors have been reported to be pharmacologically distinct from those of postsynaptic receptors in several brain areas (26-29). It has been speculated that GBR1a and GBR1b might be the structural correlates for post- and presynaptic receptors, respectively (3). Indeed, GBR1a appears to be preferentially located postsynaptically as shown by their prevalence in purified PSDs. Conversely, GBR1b IR, which was only rarely present in the PSD fraction (Fig. 8), may be preferentially localized at pre- and extrasynaptic sites. A differential localization of GBR1a and GBR1b may be mediated via the distinctive extracellular N-terminal domain, e.g. by the sushi repeats for extracellular protein contacts present exclusively on GBR1a (5).

In conclusion, the results indicate that the vast majority of GABAB receptors are represented by two populations of heterodimeric receptors GBR1a/GBR2 and GBR1b/GBR2. These two distinct receptor subtypes are localized to mainly distinct subcellular sites, with GBR1b being rarely located in postsynaptic densities. There was no indication for the presence of monomers of GBR1a, GBR1b, or GBR2 in the brain or a trimeric population of receptors containing GBR1a/GBR1b/GBR2.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Institute of Pharmacology, ETH and University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland. Tel.: 41-1-635 59 30; Fax: 41-1-635 68 74; E-mail: benke@pharma.unizh.ch.

    ABBREVIATIONS

The abbreviations used are: GABA, gamma -aminobutyric acid; GABAA, gamma -aminobutyric acid, type A; GABAB, gamma -aminobutyric acid, type B; PSD, postsynaptic densities; PAGE, polyacrylamide gel electrophoresis; IR, immunoreactivity; SPM, synaptosomal membranes.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Bowery, N. G. (1993) Annu. Rev. Pharmacol. Toxicol. 33, 109-147[Medline] [Order article via Infotrieve]
2. Misgeld, U., Bijak, M., and Jarolimek, W. (1995) Prog. Neurobiol. 46, 423-462[CrossRef][Medline] [Order article via Infotrieve]
3. Kaupmann, K., Huggel, K., Heid, J., Flor, P. J., Bischoff, S., Mickel, S. J., McMaster, G., Angst, C., Bittiger, H., Froestl, W., and Bettler, B. (1997) Nature 386, 239-246[CrossRef][Medline] [Order article via Infotrieve]
4. Fritschy, J.-M., Meskenaite, V., Honer, M., Benke, D., and Mohler, H. (1999) Eur. J. Neurosci. 11, 761-768[CrossRef][Medline] [Order article via Infotrieve]
5. Bettler, B., Kaupmann, K., and Bowery, N. (1998) Curr. Opin. Neurobiol. 8, 345-350[CrossRef][Medline] [Order article via Infotrieve]
6. Couve, A., Filippov, A. K., Connelly, C. N., Bettler, B., Brown, D. A., and Moss, S. J. (1998) J. Biol. Chem. 273, 26361-26367[Abstract/Free Full Text]
7. Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., Mosbacher, J., Bischoff, S., Kulik, A., Shigemoto, R., Karshin, A., and Bettler, B. (1998) Nature 396, 683-687[CrossRef][Medline] [Order article via Infotrieve]
8. Kuner, R., Köhr, G., Grünewald, S., Eisenhardt, G., Bach, A., and Kornau, H.-C. (1999) Science 283, 74-77[Abstract/Free Full Text]
9. Jones, K. A., Borowsky, B., Tamm, J. A., Craig, D. A., Durkin, M. M., Dai, M., Yao, W.-J., Johnson, M., Gunwaldsen, C., Huang, L.-Y., Tang, C., Shen, Q., Salon, J. A., Morse, K., Laz, T., Smith, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998) Nature 396, 674-679[CrossRef][Medline] [Order article via Infotrieve]
10. White, J. H., Wise, A., Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A. A., Emson, P., Foord, S. M., and Marshall, F. H. (1998) Nature 396, 679-682[CrossRef][Medline] [Order article via Infotrieve]
11. Ng, G. Y. K., Clark, J., Coulombe, N., Ethier, N., Hebert, T. E., Sullivan, R., Kargman, S., Chateauneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson, M. P., Liu, Q., Kolakowski, L. F., Jr., Evans, J. F., Bonner, T. I., and O'Neill, G. P. (1999) J. Biol. Chem. 274, 7607-7610[Abstract/Free Full Text]
12. Kaupmann, K., Schuler, V., Mosbacher, J., Bischoff, S., Bittiger, H., Heid, J., Froestl, W., Leonhard, S., Pfaff, T., Karschin, A., and Bettler, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14991-14996[Abstract/Free Full Text]
13. Benke, D., Mertens, S., Trceziak, A., Gillessen, D., and Mohler, H. (1991) J. Biol. Chem. 266, 4478-4483[Abstract/Free Full Text]
14. Carlin, R. K., Grab, D. J., Cohen, R. S., and Siekevitz, P. (1980) J. Cell Biol. 86, 831-845[Abstract/Free Full Text]
15. Benke, D., Cicin-Sain, A., Mertens, S., and Mohler, H. (1991) J. Recept. Res. 11, 407-424[Medline] [Order article via Infotrieve]
16. Mertens, S., Benke, D., and Mohler, H. (1993) J. Biol. Chem. 268, 5965-5973[Abstract/Free Full Text]
17. Wenzel, A., Fritschy, J. M., Mohler, H., and Benke, D. (1997) J. Neurochem. 68, 469-478[Medline] [Order article via Infotrieve]
18. Wenzel, A., Villa, M., Mohler, H., and Benke, D. (1996) J. Neurochem. 66, 1240-1248[Medline] [Order article via Infotrieve]
19. Benke, D., Wenzel, A., Scheurer, L., Fritschy, J. M., and Mohler, H. (1995) J. Recep. Sign. Transd. Res. 15, 393-411
20. Romano, C., Yang, W.-L., and O'Malley, K. L. (1996) J. Biol. Chem. 271, 28612-28616[Abstract/Free Full Text]
21. Ziff, E. B. (1997) Neuron 19, 1163-1174[CrossRef][Medline] [Order article via Infotrieve]
22. Lupas, A. (1996) Trends Biochem. Sci. 21, 375-382[CrossRef][Medline] [Order article via Infotrieve]
23. Bowery, N. G., Hudson, A. L., and Price, G. W. (1987) Neuroscience 20, 365-383[CrossRef][Medline] [Order article via Infotrieve]
24. Chu, D. M. C., Albin, R. L., Young, A. B., and Penney, J. B. (1990) Neuroscience 34, 341-357[CrossRef][Medline] [Order article via Infotrieve]
25. Turgeon, S. M., and Albin, R. L. (1994) Neuroscience 62, 601-613[CrossRef][Medline] [Order article via Infotrieve]
26. Dutar, P., and Nicoll, R. A. (1988) Neuron 1, 585-598[CrossRef][Medline] [Order article via Infotrieve]
27. Stirling, J. M., Cross, T. N., Robinson, T. N., and Green, A. R. (1989) Neuropharmacology 28, 699-704[CrossRef][Medline] [Order article via Infotrieve]
28. Harrison, N. L. (1990) J. Physiol. (Lond.) 422, 433-446[Abstract/Free Full Text]
29. Deisz, R. A., Billard, J. M., and Zieglgansberger, W. (1997) Synapse 25, 62-72[CrossRef][Medline] [Order article via Infotrieve]
30. Jordan, B. A., and Devi, L. A. (1999) Nature 399, 697-700[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Grampp, K. Sauter, B. Markovic, and D. Benke
{gamma}-Aminobutyric Acid Type B Receptors Are Constitutively Internalized via the Clathrin-dependent Pathway and Targeted to Lysosomes for Degradation
J. Biol. Chem., August 17, 2007; 282(33): 24157 - 24165.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. H. Jacobson, B. Bettler, K. Kaupmann, and J. F. Cryan
GABAB(1) Receptor Subunit Isoforms Exert a Differential Influence on Baseline but Not GABAB Receptor Agonist-Induced Changes in Mice
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1317 - 1326.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
L. H. Jacobson, P. H. Kelly, B. Bettler, K. Kaupmann, and J. F. Cryan
GABAB(1) Receptor Isoforms Differentially Mediate the Acquisition and Extinction of Aversive Taste Memories.
J. Neurosci., August 23, 2006; 26(34): 8800 - 8803.
[Abstract] [Full Text] [PDF]


Home page